New platform for clinical trials promises precision medicine for pancreatic cancer
Pancreatic cancer is the third-leading cause of cancer-related death in the United States. But across the country only 4% of patients enrol in clinical trials for the disease. Now the Pancreatic Cancer Action Network is looking to change that, and give a much-needed boost to patient outcomes, through their new initiative Precision Promise.
Precision Promise is a large-scale precision medicine trial, the first of it’s kind according to PCAN, which aims to offer patients a range of options based on their molecular profiles, and those of their tumours. The aim is to double the survival of pancreatic cancer patients by 2020.
“Precision Promise will dramatically accelerate the clinical trial process to bring promising therapies to patients faster,” said Julie Fleshman, JD, MBA, president and CEO of the Pancreatic Cancer Action Network. “Precision Promise is an unprecedented opportunity for patients and is vital to move the field forward. Instead of looking for the right patient for a clinical trial, we are designing the right clinical trial for each patient.”
PCAN have announced the initial 12 Precision Promise Clinical Trial Consortium sites that will begin enrolling patients from spring 2017. Each patients will undergo advanced molecular profiling in order to match them to the most appropriate clinical trial.
“Through Precision Promise, all data from the initial 12 Clinical Trial Consortium sites will be analyzed together so scientific findings are gathered and disseminated to the research community in a timely manner,” said Lynn Matrisian, PhD, MBA, chief research officer at the Pancreatic Cancer Action Network. “This model ensures that data and information are shared as quickly as possible for patient benefit.”